These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 31727560

  • 1. C1q/TNF-related protein-9 attenuates atherosclerosis through AMPK-NLRP3 inflammasome singling pathway.
    Zhang H, Gong X, Ni S, Wang Y, Zhu L, Ji N.
    Int Immunopharmacol; 2019 Dec; 77():105934. PubMed ID: 31727560
    [Abstract] [Full Text] [Related]

  • 2. Metformin reduced NLRP3 inflammasome activity in Ox-LDL stimulated macrophages through adenosine monophosphate activated protein kinase and protein phosphatase 2A.
    Zhang L, Lu L, Zhong X, Yue Y, Hong Y, Li Y, Li Y.
    Eur J Pharmacol; 2019 Jun 05; 852():99-106. PubMed ID: 30851273
    [Abstract] [Full Text] [Related]

  • 3. C1q/tumor necrosis factor-related protein 9 protects cultured chondrocytes from IL-1β-induced inflammatory injury by inhibiting NLRP3 inflammasome activation via the AdipoR1/AMPK axis.
    Wang B, Li Y, Hu S, Peng K.
    Environ Toxicol; 2022 Apr 05; 37(4):889-898. PubMed ID: 34990072
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Interleukin-36 receptor antagonist attenuates atherosclerosis development by inhibiting NLRP3 inflammasome.
    Tian Y, Ling XY, Chen DL, Zhang XQ, Qiu CM.
    J Cell Physiol; 2020 Dec 05; 235(12):9992-9996. PubMed ID: 32488871
    [Abstract] [Full Text] [Related]

  • 7. Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome.
    Wang Y, Ji N, Gong X, Ni S, Xu L, Zhang H.
    Endocrine; 2020 Oct 05; 70(1):65-70. PubMed ID: 32607763
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. GP73 enhances the ox-LDL-induced inflammatory response in THP-1 derived macrophages via affecting NLRP3 inflammasome signaling.
    Lin YF, Li MH, Huang RH, Zhang SZ, Xu XF, Zhou HM, Liu MH, Liao XX, Liao LZ, Guo Y, Zhuang XD.
    Int J Cardiol; 2023 Sep 15; 387():131109. PubMed ID: 37271284
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Aldehyde dehydrogenase 2 inhibited oxidized LDL-induced NLRP3 inflammasome priming and activation via attenuating oxidative stress.
    Xu Y, Yuan Q, Cao S, Cui S, Xue L, Song X, Li Z, Xu R, Yuan Q, Li R.
    Biochem Biophys Res Commun; 2020 Sep 03; 529(4):998-1004. PubMed ID: 32819611
    [Abstract] [Full Text] [Related]

  • 15. Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis.
    Chen S, Wang Y, Pan Y, Liu Y, Zheng S, Ding K, Mu K, Yuan Y, Li Z, Song H, Jin Y, Fu J.
    J Am Heart Assoc; 2020 Jun 16; 9(12):e015513. PubMed ID: 32476536
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.